• <em>Communication:</em> High-Density Lipoprotein-Specific Phospholipid Efflux in Familial Hypercholesterolemia
• A case report of an Egyptian family with familial hypercholesterolemia and an exonic LINE-1 insertion in LDLR
• A Clinical Case of Probable Sitosterolemia
• A novel equation for the estimation of low-density lipoprotein cholesterol in the Saudi Arabian population: a derivation and validation study
• A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia
• Actual nutrition in adults with familial hypercholesterolemia
• Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia
• Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
• Analysis of the Correlation between FH and PCSK9 and APOB Gene Mutations in Han and Mongolian Populations of the Hulunbuir
• ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab
• Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen
• Association Between Patient Sex and Familial Hypercholesterolemia and Long-Term Cardiovascular Risk Factor Management 5 Years After Acute Coronary Syndrome
• Barriers to and Facilitators of Implementing Guidelines for Detecting Familial Hypercholesterolaemia in Australia
• Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia
• Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries
• Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
• Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
• Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency
• Cluster analysis and visualisation of electronic health records data to identify undiagnosed patients with rare genetic diseases
• Comorbidities of Chronic Prurigo: A Systematic Review and Meta-Analysis
• Comparison of the burden of familial hypercholesterolemia between two cohorts of French Canadians hospitalized 25 years apart for coronary heart disease
• Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry
• CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing
• Current US prevalence of myocardial injury patterns and clinical outcomes among hospitalised patients with familial hypercholesterolaemia: insight from the National Inpatient Sample-a retrospective cohort study
• Diagnosis of Familial Hypercholesterolemia in Children and Young Adults
• Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China
• Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials
• Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15
• Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
• Etiology and emerging treatments for familial chylomicronemia syndrome
• Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia
• Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia
• Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy
• Evinacumab: Mechanism of action, clinical, and translational science
• Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
• Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
• Exchange Transfusion: A Good Option for the Acute Treatment of Familial Chylomicronemia Syndrome in the Neonatal Period
• Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
• Familial Hypercholesterolemia and Our Family's Heart History: From Atherosclerosis and Angina to Awareness and Advocacy
• Familial hypercholesterolemia care by Dutch pediatricians-mind the gaps
• Familial hypercholesterolemia in children and the importance of early treatment
• Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study
• Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol
• Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial
• First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population
• Genetic and clinical characteristics of patients with lipoprotein lipase deficiency from Slovenia and Pakistan: case series and systematic literature review
• Genetic association between vitamin D receptor gene and Saudi patients confirmed with Familial Hypercholesterolemia
• Genetic backgrounds and diagnosis of familial hypercholesterolemia
• Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia
• Genetic heterogeneity of familial hypercholesterolaemia in two populations from two different countries
• Genetic identification of familial hypercholesterolemia within whole genome sequences in 6820 newborns
• Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia
• Genetic Spectrum and Cascade Screening of Familial Hypercholesterolemia in Routine Clinical Setting in Hong Kong
• High Lipoprotein(a) May Explain One-Quarter of Clinical Familial Hypercholesterolemia Diagnoses in Danish Lipid Clinics
• High Prevalence of Familial Hypercholesterolemia Due to the Founder Effect of the LDLR c.2271del Variant in Communities of Oaxaca, Mexico
• Identification of a Compound Heterozygous LMF1 Variants in a Patient with Severe Hypertriglyceridemia - Case Report and Literature Review
• Impact of conducting a genetic study on the management of familial hypercholesterolemia
• Impact of the severe familial hypercholesterolemia status on atherosclerotic risks
• Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
• Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution?
• Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia
• Influence of triglyceride concentration in lipoprotein (a) as a function of dyslipidemia
• Knowledge, attitude, and practice of physicians towards familial hypercholesterolaemia in north regions of Saudi Arabia
• LDLR and PCSK9 3´UTR variants and their putative effects on microRNA molecular interactions in familial hypercholesterolemia: a computational approach
• Lipid Disorders and Pregnancy
• Lipidomic analysis identified potential predictive biomarkers of statin response in subjects with Familial hypercholesterolemia
• Long-term clinical outcomes and management of hypertriglyceridemia in children with Apo-CII deficiency
• Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand
• Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
• Longitudinal dynamics of circulating miRNAs in a swine model of familial hypercholesterolemia during early atherosclerosis
• Loss-of-Function Homozygous Variant in <em>LPL</em> Causes Type I Hyperlipoproteinemia and Renal Lipidosis
• Loss-of-Function Homozygous Variant in LPL Causes Type I Hyperlipoproteinemia and Renal Lipidosis
• Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data
• Membrane Transporter of Serotonin and Hypercholesterolemia in Children
• Modern approaches to the management of homozygous familial hypercholesterolemia in the Middle East and North Africa
• Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report
• Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease
• Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry
• Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
• Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome
• Peripheral artery disease: an underdiagnosed condition in familial hypercholesterolemia? A systematic review
• Physical signs and atherosclerotic cardiovascular disease in familial hypercholesterolemia: the HELLAS-FH Registry
• Plasma legumain in familial hypercholesterolemia: associations with statin use and cardiovascular risk markers
• Prevalence and factors associated with possible cases of familial hypercholesterolemia in Brazilian adults: a cross-sectional study
• Prevalence and management of familial hypercholesterolaemia in patients with chest pain admitted to hospital: a retrospective observational study
• Prevalence, clinical features and prognosis of familial hypercholesterolemia in Chinese Han patients with acute coronary syndrome after a coronary event: a retrospective observational study
• Putative Pathogenic Variants of <em>ABCG5</em> and <em>ABCG8</em> of Sitosterolemia in Patients With Hyper-Low-Density Lipoprotein Cholesterolemia
• Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
• Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia
• Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors
• Severe hypertriglyceridemia: Existing and emerging therapies
• Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia
• Sex differences in trends and in-hospital outcomes of acute myocardial infarction in patients with familial hypercholesterolemia: insights from a large national database
• The diagnostic value of genetic testing in familial hypercholesterolemia in patients with premature myocardial infarction
• The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
• The Health History of First-Degree Relatives' Dyslipidemia Can Affect Preferences and Intentions following the Return of Genomic Results for Monogenic Familial Hypercholesterolemia
• Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
• Universal lipid screening in adolescents to identify familial hypercholesterolemia in a large healthcare system
• Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
• Validation of the 2022 Clinical Diagnostic Criteria of Familial Hypercholesterolemia in Japan